Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26693072
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Am+J+Cancer+Res
2015 ; 5
(10
): 3221-30
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
MHC I-related chain a expression in gastric carcinoma and the efficacy of
immunotherapy with cytokine-induced killer cells
#MMPMID26693072
Chen Y
; Lin J
; Guo ZQ
; Lin WS
; Zhou ZF
; Huang CZ
; Chen Q
; Ye YB
Am J Cancer Res
2015[]; 5
(10
): 3221-30
PMID26693072
show ga
Cytokine-induced killer (CIK) cells have shown promising activity against gastric
cancer in vitro and in vivo. Previous studies showed that cell signaling through
MHC I-related Chain A (MICA)-Natural killer group 2, member D (NKG2D) results in
CIK cell activation leading to cytolytic activities against tumor cells. In this
study, we investigate the MICA status in patients with gastric carcinoma, and
determine the potential relationship between MICA and clinical outcome of a CIK
containing therapy. Two hundred and forty-three patients with gastric cancer who
had received curative D2 gastrectomy were enrolled. The MICA expression of their
tumors was determined by immunohistochemistry (IHC). Disease-free survival (DFS)
and overall survival (OS) were evaluated. One hundred and forty-eight patients
received adjuvant chemotherapy alone, and 95 patients received adjuvant
chemotherapy combined with autologous CIK cell therapy. Patients who received
adjuvant chemotherapy plus CIK had significantly longer DFS, 42.0 months vs. 32.0
months (P = 0.012), and OS, 45.0 months vs. 42.0 months (P = 0.039), by log-rank
test. MICA high-expression, IHC scores of 5-7, was found in tumors from 89 of 243
patients (36.6%). The MICA expression was significantly correlated with the stage
(P = 0.007) and there was a borderline association with histological grade (P =
0.054). In the adjuvant chemotherapy plus CIK group (n = 95), patients with high
MICA expression had longer DFS, 46.0 months vs. 41.0 months (P = 0.027), and OS,
48.0 months vs. 42.0 months (P = 0.031). In the adjuvant chemotherapy alone group
(n = 148), the median DFS and OS had no significant correlation with the MICA
status. In a multivariate analysis stage, CIK therapy, and the interaction of
MICA status and CIK therapy were independent prognostic factors for DFS and OS.
Our study indicated that adjuvant chemotherapy plus CIK immunotherapy is a
promising modality for treating gastric cancer patients after D2 gastrectomy.
MICA status was associated with the outcome measures in CIK therapy, validation
in prospective clinical trials is required to assess the value of this biomarker
in the clinical decision-making process.